Open registration: nanobodies and next-generation antibody platforms, with Weisheng Chen, September 19
Episode 3 of NAPPA Healthcare & Biopharma Insights looks past conventional IgG to single-domain antibodies and the discovery platforms behind them.
NAPPA’s thought-leadership webinar series — NAPPA Healthcare & Biopharma Insights — continues on Saturday, September 19, 2026, 9:00–10:00 PM ET with Episode 3: Beyond IgG: Nanobodies and the Next Generation of Diagnostics & Therapeutics.
The episode is led by Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen, a pioneer in next-generation antibody discovery platforms whose work spans single-domain, common light chain, and full-length antibody discovery, alongside mRNA therapeutics and gene and cell therapies.
What’s covered
- What nanobodies are, and how they differ from conventional IgG
- Single-domain, common light chain, and full-length antibody discovery
- Next-generation antibody discovery platforms
- Applications across diagnostics, therapy, and drug development
- mRNA therapeutics and gene & cell therapies
Register
Registration is free for NAPPA members and qualified industry guests. Seats are limited; join details are sent by email after registering.